Desandes Emmanuel, Lacour Brigitte, Sommelet Danièle, White-Koning Mélanie, Velten Michel, Tretarre Brigitte, Marr Angelina, Maarouf Nabil, Guizard Anne-Valérie, Delafosse Patricia, Danzon Arlette, Cotte Christine, Brugieres Laurence
French National Registry of Childhood Solid Tumours, Vandoeuvre-lès-Nancy, France.
Eur J Oncol Nurs. 2007 Feb;11(1):74-81. doi: 10.1016/j.ejon.2006.04.036. Epub 2006 Jun 30.
We report an adolescent cancer pathway from referral, through diagnosis and treatment, to follow-up in France. All cases of cancer among 15-19 years, diagnosed from 1988 to 1997, recorded by nine French population-based cancer registries (10% of French population) were included. The management of adolescent cancer by paediatricians was rare. An adolescents' pathway through cancer care can be summarized as first visit to general practitioner, referral to adult oncologist for haematological malignancy and medical or surgical specialists for solid tumours, treatment in adult unit, and follow-up by adult oncologist, adult medical or surgical specialist, or general practitioner. Only 9% of the 15-19 years are entered into a clinical trial (respectively 6% and 3% into adult and paediatric clinical trial). The inclusion rate changes according to the diagnosis, higher for acute lymphoblastic leukaemia (39%), non-Hodgkin's lymphomas (NHL) (27%), and acute non-lymphoblastic leukaemia (20%). Only 4% of adolescent cancers were managed on shared adult/paediatric departments, especially for soft-tissue sarcomas (14.9%), malignant bone tumours (13.4), central nervous system tumours (6.2%), and NHL (4.4%). Whatever the reasons for lack of participation in clinical trials, an ideal model requiring communication and cooperation between all adult and paediatric specialists involved in adolescent cancer treatment should reduce the large gap in access to cooperative groups.
我们报告了法国青少年癌症从转诊、诊断、治疗到随访的整个流程。纳入了1988年至1997年期间由9个法国基于人群的癌症登记处(覆盖法国10%的人口)记录的所有15至19岁的癌症病例。儿科医生对青少年癌症的管理很少见。青少年癌症护理的流程可概括为:首次就诊于全科医生,对于血液系统恶性肿瘤转诊至成人肿瘤学家,对于实体瘤转诊至医学或外科专科医生,在成人科室进行治疗,由成人肿瘤学家、成人医学或外科专科医生或全科医生进行随访。15至19岁的患者中只有9%进入临床试验(分别有6%和3%进入成人和儿科临床试验)。纳入率因诊断而异,急性淋巴细胞白血病(39%)、非霍奇金淋巴瘤(NHL)(27%)和急性非淋巴细胞白血病(20%)的纳入率较高。只有4%的青少年癌症在成人/儿科联合科室进行管理,特别是软组织肉瘤(14.9%)、恶性骨肿瘤(13.4%)、中枢神经系统肿瘤(6.2%)和NHL(4.4%)。无论不参与临床试验的原因是什么,一个需要参与青少年癌症治疗的所有成人和儿科专家进行沟通与合作的理想模式应能缩小参与合作组机会方面的巨大差距。